… (proprotein convertase subtilisin/kexin type 9) inhibitor can further reduce the risk of … PCSK9
inhibitors.Any concerns about efficacy and safety of PCSK9 inhibition specifically in Asian …

… PCSK9 inhibited the elimination of LDL-C. The decreasing … Since no Asian subjects with
hypercholesterolaemia were … the PCSK9 values of Asian hypercholesterolaemia subjects. The …

… a PCSK9 inhibitor with … PCSK9 monoclonal antibodies have been approved in the clinic,
we are the first to report the clinical investigation of a novel and potential long-acting PCSK9 …

… Asia. Given the current state, driven to some degree by “ability and willingness to pay” for
PCSK9 inhibitors, … More than 5 years after the launch of PCSK9 inhibitors, we have realistic …

… In Asia, data on the efficacy of PCSK9 inhibitors in real-world practice under the local or
national reimbursement criteria are still limited. This study aimed to describe the clinical …

… intron sequences of PCSK9 in the 32 subjects with the lowest … subjects 3363 Fluorogenic
5′-nucleotidase assays for the … PCSK9 E670G polymorphism should be considered in Asian …

… Informed consents were obtained from all subjects. ACS patients … Compared to statin alone,
a combination therapy of PCSK9 inhibitor … particles subfractions in patients with ACS in Asia. …

… Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly lower LDL-C …
The review presents the associated mechanisms of the beneficial effects of PCSK9 inhibitors …

… Patients in the lower LDL-C subgroup were more likely to be South American or Asian, to
have diabetes, and to be treated with high-intensity statins and had higher triglyceride and …

… /kexin type 9 (PCSK9) provide insights into … target PCSK9 lower LDL cholesterol (LDL-C)
levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors …